Compactin works by pretending to be a molecule the body uses to make cholesterol, so it blocks the key step in cholesterol production.
Claim Context
Compactin functions as a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, by mimicking the structure of HMG-CoA, thereby blocking the enzymatic conversion of HMG-CoA to mevalonate in the mevalonate pathway.
“Compactin shared structural similarities with HMG-CoA and proved to be a potent competitive inhibitor of HMG-CoA reductase.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Could demonstrate clinical reduction in LDL cholesterol in humans due to HMG-CoA reductase inhibition.
A double-blind RCT of 500 adults with hypercholesterolemia randomized to compactin 20 mg/day vs placebo for 12 weeks, measuring changes in LDL-C, HDL-C, triglycerides, and liver enzymes as primary outcomes.
Could show long-term association between statin use and reduced cardiovascular events.
A prospective cohort of 10,000 patients with high cholesterol followed for 10 years, comparing incidence of heart attack and stroke in those prescribed statins vs not.
Could document initial observations of cholesterol lowering in animal or human subjects treated with compactin.
A 1976 case series of 5 rats treated with compactin, reporting serum cholesterol levels before and after 7 days of treatment, along with liver enzyme activity assays.